Ibn Sina posts 33% EPS growth in 9-month despite Q3 dip
Meanwhile, the company’s consolidated net asset value (NAV) increased to Tk434.61 crore, up from Tk392.69 crore in the previous period
Ibn Sina Pharmaceutical Industry PLC reported a strong growth in earnings for the first nine months of the current fiscal year, despite a decline in its third-quarter performance.
According to its price-sensitive information, the company's consolidated earnings per share (EPS) rose to Tk19.94 during the July-March period, marking a 32.75% increase compared to the same period in the previous fiscal year.
The company's board approved the third-quarter financial statements at a meeting held today (22 April) in line with listing regulations. The financials are yet to be audited.
Keep updated, follow The Business Standard's Google news channel
However, in the third quarter alone (January-March), the company's EPS declined by 16% to Tk4.67, down from Tk5.55 recorded in the corresponding period a year earlier.
Meanwhile, the company's consolidated net asset value (NAV) increased to Tk434.61 crore, up from Tk392.69 crore in the previous period.
